| Chemical Information | |
| Antiviral agent ID | DrugRepV_3076 | |
| Antiviral agent name | Abamectin | |
| IUPAC Name | 6-(butan-2-yl)-21',24'-dihydroxy-12'-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-5,11',13',22'-tetramethyl-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.1?,?.0²?,²?]pentacosane]-10',14',16',22'-tetraen-2'-one |  |
| SMILES (canonical) | CCC(C)C1C(C=CC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C | |
| SMILES (isomeric) | CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4(C(C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C | |
| Molecular Formula | C48H72O14 | |
| Molecular Weight (g/mol) | 873.09 | |
| InChl | InChI=1S/C48H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,17-19,25-26,28,30-31,33-45,49-50,52H,11,16,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35?,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1 | |
| Structural Information | |
 |
|
| Clinical Information | |
|
Primary Indication (Clinical trial phases) | Terminated
|  |
| Biological Information | |
|
Primary Indication (Disease Category) | Infectious Disease
| |
|
Primary Indication (Disease) | Helmintic infection
| |
|
Secondary Indication | Chikungunya virus (CHIKV) NA CHIKV-Rluc |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | BHK-21
| |
|
Secondary Indication (Mode of viral infection) | Transfection
| |
|
Secondary Indication (Viral titer) | 0.01 MOI
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 16 hours
| |
|
Secondary Indication (Drug concentration) | 3 μM
| |
|
Secondary Indication (Cell based assay) | Plaque assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Log reduction [ 3.5 Log ] | |
|
Reference | Varghese FS, Kaukinen P, GlÌÄå_sker S, Bespalov M, Hanski L, Wennerberg K, KÌÄå_mmerer BM, Ahola T..Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphavi.Antiviral Res. 2016 Feb;126:117-24. doi: 10.1016/j.antiviral.2015.12.012. Epub 2016 Jan 2. PMID:26752081
|  |
|
Comment | Abamectin and ivermectin are fermentation products generated by a soil dwelling actinomycete, Streptomyces avermitilis, whereas berberine is a plant-derived isoquinoline alkaloid.These drugs inhibits Chikungunya virus, Semliki forest virus and Sindbis virus replication in dose-dependent manner. Abamectin and ivermectin were also active against yellow fever virus.
| |